Abstract 1982P
Background
KS, associated with human herpesvirus 8 (KSHV) infection, is a tumor originating from endothelial cells. As a common tumor associated with AIDS, KS is typically more aggressive in HIV-positive (HIV+) than in HIV-negative (HIV-) patients (pts). While antiretroviral therapy helps control KS in HIV+ pts, chemotherapy remains the first-line treatment (Tx) in advanced KS but is limited by modest responses and dose-limiting toxicities. The TME has been shown to play a critical role in KS development and progression. Here, we sought to understand the TME in KS, with a specific focus on the differences in HIV status.
Methods
Whole transcriptomic profiling was performed on 13 retrospective samples from 9 pts (HIV+: n = 6, HIV- n =3; mostly baseline, except 2 HIV- and 2 HIV+ pts had paired samples before and after Tx). A deconvolution algorithm Kassandra was used to predict cellular composition with pre-training on sarcoma samples, and EdgeR was used for differential expression analysis. TME subtypes were classified based on a previous study (Bagaev et al., 2021) assessing sarcoma-related gene expression patterns.
Results
All KS samples were enriched with endothelial cells and had characteristics of a typical sarcoma TME with an abundance of macrophages and normal amounts of B cells. Most HIV- pts had an Immune-Enriched, Non-fibrotic subtype, while HIV+ pts had immune-Enriched, Fibrotic or Fibrotic TMEs. Decreased angiogenic signatures were observed after Tx in HIV+ pts with paired samples. Expression levels of chemokines (CXCL2, CXCL8, CXCL11), chemokine receptors (CCR1-7, CXCR1-2), and CCL factors were higher in pre-Tx HIV- pts versus post-Tx and post-TX HIV+ pts versus pre-TX. PD-L1 and PD-L2 expressions were higher in HIV- pts before Tx and in HIV+ pts after Tx. In 3 HIV- and 2 HIV+ pts, for whom TCR.
Conclusions
Our results showed distinct transcriptomic features and TMEs between HIV+ and HIV- KS in responses to Tx. Future larger cohorts and research into the unique T cell clonotypes may help yield novel therapeutic avenues in KS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
BostonGene, Corp. and Albert Einstein College of Medicine.
Funding
BostonGene, Corp.
Disclosure
A. Sevkoplyas, S. Podsvirova, A. Tyshevich, K. Zornikova, N. Shin, N. Kotlov, E. Postovalova: Financial Interests, Institutional, Full or part-time Employment: BostonGene, Corp.; Financial Interests, Institutional, Stocks/Shares: BostonGene, Corp.. L. Paoluzzi: Financial Interests, Institutional, Full or part-time Employment: Regeneron; Financial Interests, Institutional, Stocks/Shares: Regeneron. All other authors have declared no conflicts of interest.
Resources from the same session
1981P - Histopathological diagnostic discrepancies in bone and soft tissue tumors referred to a specialist sarcoma center and its clinical impact
Presenter: Akira Kawai
Session: Poster session 15
1983P - Palliative spatially fractionated stereotactic radiation therapy (Lattice) for large sarcoma
Presenter: Gabriela Studer
Session: Poster session 15
1984P - Sex differences in anticancer treatment delivery and toxicity in patients with sarcoma in a reference center
Presenter: Ilaria Tortorelli
Session: Poster session 15
1985P - Expert sarcoma care is the need of the hour: Diagnostic and management challenges at a tertiary-care centre in India
Presenter: Ghazal Tansir
Session: Poster session 15
1986P - Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: An analysis from the OnCovid registry
Presenter: Alessandro Mazzocca
Session: Poster session 15
1987TiP - Pembrolizumab in combination with eftilagimod alpha and radiotherapy in neoadjuvant treatment of patients with soft tissue sarcomas: EFTISARC-NEO trial
Presenter: Katarzyna Kozak
Session: Poster session 15
2213P - Impact of the diagnosis-to-treatment interval on the survival of patients with papillary thyroid cancer
Presenter: Tingting Wei
Session: Poster session 15
2214P - Identification of prognosis-associated genes in locally advanced well-differentiated thyroid cancer using TCGA cohort analysis
Presenter: Ah Ra Jung
Session: Poster session 15
2216P - Clinicopathologic and genetic characteristics of patients of different ages with diffuse sclerosing variant papillary thyroid carcinoma
Presenter: Soo Young Kim
Session: Poster session 15
2220P - MOLTHY project (TTCC-2020-02): A Spanish observational study for MOLecular characterization of THYroid carcinoma
Presenter: Neus Baste Rotllan
Session: Poster session 15